GH vs GRAL: stock comparison and AI forecast
Guardant Health, Inc. (GH) and Grail, Inc. (GRAL) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
GH Guardant Health, Inc.
- Price
- $150.87 +63.5% · 6M
- Market Cap
- $20.25B
- P/E Ratio
- –
- Size
- large-cap
- AI Forecast
GRAL Grail, Inc.
- Market Cap
- $5.42B
- P/E Ratio
- –
- Size
- mid-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- GH is 3.7 times larger than GRAL by market capitalization ($20.25B against $5.42B).
- GH turns -37.9% of its revenue into net income, against -243.8% for GRAL.
- Both companies share the SEC industry classification Services-Medical Laboratories.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | GH | GRAL |
|---|---|---|
| Market Cap | $20.25B | $5.42B |
| P/B Ratio | – | 2.21x |
| EPS | $-3.61 | $-9.44 |
| Book Value/Share | – | $54.93 |
| Revenue/Share | $9.53 | $3.73 |
| FCF/Share | $-1.73 | $-6.99 |
Profitability & Margins
| Metric | GH | GRAL |
|---|---|---|
| ROE | – | -16.6% |
| ROA | -25.7% | -14.9% |
| ROIC | -33.3% | -21.9% |
| Gross Margin | 65.2% | – |
| Operating Margin | -39.4% | -347.3% |
| Net Margin | -37.9% | -243.8% |
| EBT Margin | -38.0% | -329.0% |
| Tax Rate | 0.2% | 25.9% |
Financial Health
| Metric | GH | GRAL |
|---|---|---|
| Current Ratio | 3.60x | 8.93x |
| Quick Ratio | 3.35x | – |
| D/E Ratio | – | 0.11x |
| Financial Leverage | – | 1.11x |
| Interest Coverage | -98.7x | – |
| Working Capital | $970M | $748M |
Cash Flow
| Metric | GH | GRAL |
|---|---|---|
| Operating Cash Flow | -$173M | -$306M |
| Free Cash Flow | -$232M | -$312M |
| Capital Spending | -$59M | -$6M |
| FCF/Sales | -18.1% | -187.3% |
| CapEx/Sales | 4.6% | 3.5% |
Operational Efficiency
| Metric | GH | GRAL |
|---|---|---|
| Asset Turnover | 0.68x | 0.06x |
| Receivables Turnover | 6.9x | 8.8x |
| Inventory Turnover | 4.8x | – |
| Fixed Assets Turnover | 8.4x | 3.9x |
| Days Sales Outstanding | 53 days | 42 days |
| Days Inventory | 77 days | – |
| Payables Period | 84 days | – |
| Cash Conversion Cycle | 46 days | – |
Income Statement
| Metric | GH | GRAL |
|---|---|---|
| Total Revenue | $1.28B | $167M |
| Operating Income | -$504M | -$579M |
| Net Income | -$485M | -$406M |
| R&D Expense | $387M | $186M |
| SG&A Expense | $1.41B | $435M |
| Cost of Goods Sold | $445M | – |
Dividend & Shareholder Information
| Metric | GH | GRAL |
|---|---|---|
| Shares Outstanding | 134M | 45M |
GH vs GRAL: stock comparison and AI forecast
Which is bigger, GH or GRAL?
GH is 3.7 times larger than GRAL by market capitalization ($20.25B against $5.42B).
Which one does Intratio's AI model rank higher, GH or GRAL?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.